Continuous intragastric pH monitoring: a real progress in the assessment of antisecretory drugs
- PMID: 1983412
Continuous intragastric pH monitoring: a real progress in the assessment of antisecretory drugs
Abstract
24 hour intragastric pH recording by means of an indwelling minielectrode which is connected to an ambulatory apparatus is unquestioned in the assessment of the pharmacodynamic properties of potent antisecretory drugs. pH measurements obtained with this continuous monitoring have been shown to be more accurate than those provided by the traditional hourly nasogastric aspiration method. We used this technique to evaluate the effects on gastric acidity of placebo, ranitidine 150mg, famotidine 20mg and nizatidine 150mg in fifteen patients with healed duodenal ulcer. These medications were orally administered at 22:00hr in a double-blind fashion on four separate occasions at least one week apart. All H2-receptor blockers were more effective than placebo in suppressing both circadian (p less than 0.001) and nocturnal (p less than 0.0001) gastric acidity, while there was no significant difference between the effects of the three active agents in the same time periods. During morning hours (8:00-12:00) both ranitidine and nizatidine did not differ from placebo, and famotidine produced more acid inhibition than nizatidine (p less than 0.03). However, in the same period the percent of time spent above pH 4.0 was significantly superior (p less than 0.00001) for both famotidine (33%) and ranitidine (14.2%) with respect to nizatidine (6%) and placebo (8.4%). Therefore, after bedtime dosing, the action of nizatidine is more confined to the nocturnal period than those of ranitidine and famotidine.
Similar articles
-
Comparison of the effects of placebo, ranitidine, famotidine and nizatidine on intragastric acidity by means of continuous pH recording.Digestion. 1989;42(1):1-6. doi: 10.1159/000199818. Digestion. 1989. PMID: 2568299 Clinical Trial.
-
Do anticholinergics interact with histamine H2 receptor antagonists on night intragastric acidity in active duodenal ulcer patients?Am J Gastroenterol. 1988 Dec;83(12):1371-5. Am J Gastroenterol. 1988. PMID: 2904218 Clinical Trial.
-
Twenty-four-hour control of gastric acidity by twice-daily doses of placebo, nizatidine 150 mg, nizatidine 300 mg, and ranitidine 300 mg.J Clin Pharmacol. 1993 Jan;33(1):70-4. doi: 10.1002/j.1552-4604.1993.tb03906.x. J Clin Pharmacol. 1993. PMID: 8429117 Clinical Trial.
-
Acid secretion and acid suppression in pathogenesis and healing of peptic ulcer disease.Hepatogastroenterology. 1990 Jul;37 Suppl 1:18-28. Hepatogastroenterology. 1990. PMID: 1976583 Review.
-
Clinical review of histamine2 receptor antagonists.Arch Intern Med. 1990 Apr;150(4):745-51. Arch Intern Med. 1990. PMID: 1970232 Review.
Cited by
-
Eradication of Helicobacter pylori restores the inhibitory effect of cholecystokinin on postprandial gastrin release in duodenal ulcer patients.Gut. 1995 Oct;37(4):482-7. doi: 10.1136/gut.37.4.482. Gut. 1995. PMID: 7489932 Free PMC article.
-
Cholecystokinin in the control of gastric acid secretion in man.Gut. 1993 Mar;34(3):321-8. doi: 10.1136/gut.34.3.321. Gut. 1993. PMID: 8472978 Free PMC article.